Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Benzalkonium chloride; Triclosan; Light liquid paraffin
Clonmel Healthcare Ltd
D08AJ; D08AJ01
Benzalkonium chloride; Triclosan; Light liquid paraffin
52.5/6/2 percent weight/weight
Bath additive
Quaternary ammonium compounds; benzalkonium
Not marketed
1989-05-25
Health Products Regulatory Authority 04 November 2019 CRN0098VT Page 1 of 3 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Oilatum Plus Bath Additive Light liquid paraffin 52.5% w/w Benzalkonium chloride 6.0% w/w Triclosan 2.0% w/w 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Light liquid paraffin 52.5 % w/w Benzalkonium chloride 6.0 % w/w Triclosan 2.0 % w/w For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Bath additive. A clear, pale yellow oily solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of infected eczemas and eczemas at risk from infection. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oilatum Plus should always be diluted with water. It is an effective cleanser and should not be used with soap. Bath: In an eight inch bath add 2 capfuls; in a four inch bath add 1 capful. Infant bath: Add 1 ml (just sufficient to cover the bottom of the cap) and mix well with water. Soak for 15 minutes, gently pat the skin dry with a clean towel. Use once daily. 4.3 CONTRAINDICATIONS Patients with known hypersensitivity to any of the ingredients should not use the product. Not recommended for babies younger than 6 months. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Avoid contact of the undiluted product with the eyes. Take care to avoid slipping in the bath. 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONS None known. 4.6 FERTILITY, PREGNANCY AND LACTATION There are no restrictions on the use of Oilatum Plus in pregnancy and lactation. Health Products Regulatory Authority 04 November 2019 CRN0098VT Page 2 of 3 4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES None. 4.8 UNDESIRABLE EFFECTS None known. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfo Read the complete document